Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 11, Issue 1, 2008, Pages 46-52

  Fleshner, N ^a   Keane, T E ^b   Lawton, C A ^c   Mulders, P F ^d   Payne, H ^e   Taneja, S S ^f   Morris, T ^g  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MIDDLESEX HOSPITAL   (United Kingdom)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; DOCETAXEL; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN;

ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FEVER; EVIDENCE BASED MEDICINE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LONG TERM CARE; MEDICAL DECISION MAKING; MYALGIA; ORCHIECTOMY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS, HORMONAL; GOSERELIN; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 39149123530     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500982     Document Type: Article

References (42)

1. Frei III E, Gehan EA. Definition of cure for Hodgkin's disease. Cancer Res 1971; 31: 1828-1833.
2. Johansson J-E, Holmberg L, Johansson S, Bergström P, Adami H-O. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997; 277: 467-471.
3. Gattellari M, Butow PN, Tattersall MH, Dunn SM, MacLeod CA. Misunderstanding in cancer patients: Why shoot the messenger? Ann Oncol 1999; 10: 39-46.
4. Hill C. How many cancers are cured? Bull Cancer 1998; 85: 745.
5. Laguna MP, Pizzocaro G, Klepp O, Algabá F, Kisbenedek L, Leiva O. EAU guidelines on testicular cancer. Eur Urol 2001; 40: 102-110.
6. Williams SD, Stablein DM, Einhorn LH, Muggia FM, Weiss RB, Donohue JP et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987; 317: 1433-1438.
7. Jones RH, Vasey PA. Part II: Testicular cancer - management of advanced disease. Lancet Oncol 2003; 4: 748-747.
8. Saxman SB, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indian University experience. J Clin Oncol 1998, 16: 702-706.
9. Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Therapy-related malignancies following, treatment of germ cell cancer. Int J Cancer 1999; 83: 860-863.
10. Sengupta N, Siddiqui E, Mumtaz FH. Cancers of the bladder. J R Soc Health 2004; 124: 228-229.
11. Hassen W, Droller MJ. Current concepts in assessment and treatment of bladder cancer. Curr Opin Urol 2000; 10: 291-299.
12. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003; 169: 1706-1708.
13. Danesi DT, Arcangeli G, Cruciani E, Altavista P, Mecozzi A, Saracino B et al. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: Long term results. Cancer 2004; 101: 2540-2548.
14. Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF et al. Surgical factors influence bladder cancer outcomes: A cooperative group report. J Clin Oncol 2004; 22: 2781-2789.
15. Srougi M, Simon SD. Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: A 5-year followup. J Urol 1994; 151: 593-597.
16. Fellin G, Graffer U, Bolner A, Ambrosini G, Caffo O, Luciani L. Combined chemotherapy and radiation with selective organ preservation for muscle invasive bladder carcinoma. A single-institution phase II study. Br J Urol 1997; 80: 44-49.
17. Lamm DL, Torti FM. Bladder cancer, 1996. CA Cancer J Clin 1996; 46: 93-112.
18. Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003; 4: 489-497.
19. Mickisch G, Carballido J, Hellsten S, Schulze H, Mensink H. Guidelines on renal cell cancer. Eur Urol 2001; 40: 252-255.
20. Atzpodien J, Hoffmann R, Franzke M, Stief C, Wandert T, Reitz M. Thirteen-year, long-term efficacy of interferon 2 alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer 2002, 95: 1045-1050.
21. Jordan Jr WP, Blackard CE, Byar DP. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 1977; 70: 1411-1413.
22. Jani AB, Hellman S. Early prostate cancer: Clinical decision-making. Lancet 2003; 361: 1045-1053.
23. Lieberfarb ME, Schultz D, Whittington R, Malkowicz B, Tomaszewski JE, Weinstein M et al. Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy. Int J Radiat Oncol Biol Phys 2002; 53: 898-903.
24. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA et al. Radiation therapy for clinically localized prostate cancer. A multi-institutional pooled analysis. JAMA 1999; 281: 1598-1604.
25. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H et al. European Association of Urology Guidelines on Prostate Cancer. Eur Urol 2005; 48: 546-551.
26. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004; 22: 2927-2941.
27. Zagars GK, Ayala AG, von Eschenbach AC, Pollack A. The prognostic importance of Gleason grade in prostatic adencicarcinoma: A long-term followup study of 648 patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 1995; 31: 237-245.
28. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167: 528-534.
29. Lee WR, Hanks GE, Schultheiss TE, Corn BW, Hunt MA. Localized prostate cancer treated by external-beam radiotherapy alone: Serum prostate-specific antigen - driven outcome analysis. J Clin Oncol 1995, 13: 464-469.
30. Lee HM, Solan MJ, Lupinacci P, Gomella LG, Valicenti RK. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): Effect of adjuvant radiotherapy. Urology 2004, 64: 84-89.
31. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001; 165: 119-125.
32. May F, Hartung R, Breul J. The ability of the American Joint Committee on Cancer Staging system to predict progression-free survival after radical prostatectomy. BJU Int 2001; 88: 702-707.
33. Messing E, Manola J, Wilding G, Sarosdy M, Crawford D, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-1788.
34. Messing E, Manola J, Sarosdy M, Wilding G, Crawford ED. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectorny in men with node positive prostate cancer: results at 10 years of EST 3886. J Urol 2003; 169: 396 abs 1480.
35. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B et al. Androgen suppression adjuvant to definitive radiotherapy in carcinomas of the prostate - long term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-1290.
36. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.
37. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO et al Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002; 360: 103-108.
38. Fridmans A, Chertin B, Koulikov D, Lindenberg T, Gelber H, Leiter C et al. Reversibility of androgen deprivation therapy in patients with prostate cancer. J Urol 2005; 173: 784-789.
39. Shahidi M, Norman AR, Gadd J, Huddart RA, Horwich A, Dearnaley DP, Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer. Clin Oncol (R Coll Radiol) 2001; 13: 291-295.
40. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21: 3972-3978.
41. Beer TM, Bubalo JS. Complications of chemotherapy for prostate cancer. Semin Urol Oncol 2001; 19: 222-230.
42. Hedlund PO. Side effects of endocrine treatment and their mechanisms: castration, antiandrogens, and estrogens. Prostate Suppl 2000; 10: 32-37.